ZYDUSLIFE Zydus Lifesciences Q1 FY26 results (Apr–Jun 2025) and concall
Zydus Lifesciences reported a strong start to FY26 with consolidated revenues of ₹65.7 billion, up 6% YoY, and a robust EBITDA margin of 31.8%. The company's net cash position significantly improved to ₹56.3 billion. While international markets and India branded formulations showed strong growth, net profit growth was a more modest 3% YoY, and the Consumer Wellness segment faced seasonal challenges.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 2,621 | 2,516 | 5,820 | 2,588 |
| EBITDA | 942 | 648 | 3,773 | 585 |
| Net profit | 790 | 471 | 2,814 | 385 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
